AndroGel Dose Adjustments for South Asian Patients

Why South Asian Men Need a Different Starting Dose

South Asian men present a distinct cardiometabolic profile that changes how testosterone replacement therapy should be initiated. The combination of earlier diabetes onset, lower BMI thresholds for visceral adiposity, and high prevalence of the UGT2B17 deletion polymorphism means standard AndroGel dosing protocols may overshoot therapeutic targets or amplify cardiovascular risk in this population.

The Cardiometabolic Backdrop

The WHO Expert Consultation on BMI in Asian populations established that South Asian individuals accumulate visceral fat and develop insulin resistance at BMI values 2 to 3 points lower than European counterparts [1]. A South Asian man with a BMI of 23 carries the same metabolic risk as a European man with a BMI of 25 or higher. This distinction matters because testosterone replacement therapy itself alters lipid profiles, hematocrit, and insulin sensitivity. Starting at a standard dose in someone already carrying elevated baseline risk compresses the safety margin.

Earlier Cardiometabolic Disease Onset

The MASALA (Mediators of Atherosclerosis in South Asians Living in America) study documented that South Asian Americans develop type 2 diabetes roughly a decade earlier than other U.S. Populations, even after controlling for BMI and waist circumference [2]. The Endocrine Society's 2018 clinical practice guideline for testosterone therapy states that clinicians should "assess cardiovascular risk factors before initiating testosterone therapy" and monitor hematocrit, lipids, and PSA at regular intervals [3]. When baseline cardiometabolic risk is already elevated, this guidance takes on additional weight.

Connecting Risk to Dose Selection

The T-Trials (Testosterone Trials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with low testosterone, found that testosterone gel increased coronary artery plaque volume as measured by coronary CT angiography [4]. While the T-Trials did not publish ethnicity-stratified dosing arms, the cardiovascular signal reinforces why a lower starting dose is reasonable in populations with pre-existing vascular vulnerability. Starting low and titrating based on serum levels every 4 weeks is a safer path than beginning at 50 mg daily and adjusting downward after adverse lab findings emerge.

Pharmacogenomic Factors Affecting AndroGel Metabolism

Genetic variation in testosterone glucuronidation and sex hormone-binding globulin (SHBG) levels directly affects how South Asian men process transdermal testosterone. These are not theoretical concerns. They produce measurable differences in serum drug levels at identical doses.

UGT2B17 Deletion Polymorphism

The UGT2B17 gene encodes a UDP-glucuronosyltransferase enzyme responsible for a major portion of testosterone phase II metabolism. A whole-gene deletion polymorphism (del/del genotype) is found in approximately 67% of East Asian and 22 to 40% of South Asian men, compared to roughly 10% of European men [5]. Men homozygous for this deletion clear testosterone more slowly, resulting in higher serum levels at the same applied dose. PharmGKB classifies UGT2B17 as a pharmacogene relevant to androgen metabolism [6].

For South Asian patients with the del/del genotype, a standard 50 mg daily dose of AndroGel 1% can push trough testosterone above 800 ng/dL, a level associated with increased erythrocytosis risk. Starting at 25 mg daily and measuring trough testosterone at 4 weeks catches this elevation before hematocrit climbs.

SHBG and Free Testosterone Dynamics

South Asian men with insulin resistance frequently have lower SHBG concentrations. Lower SHBG means a larger fraction of total testosterone circulates in the biologically active free form. A study published in the Journal of Clinical Endocrinology & Metabolism found that SHBG levels were significantly lower in South Asian men compared with European men, independent of BMI [7]. When starting AndroGel, checking both total testosterone and calculated free testosterone (or equilibrium dialysis) ensures the dose accounts for this shift. A total testosterone of 500 ng/dL with low SHBG can produce the same tissue androgenization as 700 ng/dL with normal SHBG.

CYP Enzyme Variability

CYP3A4 and CYP19A1 (aromatase) also contribute to testosterone metabolism and estrogen conversion. Population-level data from PharmGKB show that CYP3A4*1G, a reduced-function allele, occurs at higher frequencies in South and East Asian populations compared with European groups [6]. Reduced CYP3A4 activity can slow testosterone oxidation, compounding the effect of UGT2B17 deletion. This dual slowdown makes conservative initial dosing especially relevant.

Recommended Dosing Protocol

The goal is the same as for any man with hypogonadism: restore testosterone to the mid-normal range (400 to 600 ng/dL trough) while keeping hematocrit below 54%, monitoring lipids, and screening for sleep apnea. The path to that goal should be adjusted.

Starting Dose

For AndroGel 1.62%, begin at 20.25 mg/day (one pump actuation) rather than the standard 40.5 mg/day. For AndroGel 1%, begin at 25 mg/day (half the standard 50 mg packet or two pumps of the metered-dose pump) rather than the standard 50 mg/day. This lower starting point reduces the probability of supratherapeutic levels in men with UGT2B17 deletion and/or low SHBG.

Titration Schedule

Draw serum total testosterone, free testosterone, hematocrit, and a fasting lipid panel at baseline. Repeat total testosterone (trough, drawn 2 to 4 hours after morning application per the Endocrine Society guideline [3]) and hematocrit at 4 weeks. If trough testosterone is below 400 ng/dL and hematocrit remains below 50%, increase to the next dose step: 40.5 mg/day (1.62%) or 50 mg/day (1%). Repeat labs at 8 weeks after dose adjustment.

When to Hold or Reduce

Stop dose escalation and reassess if any of the following occur at any titration visit:

• Hematocrit exceeds 54%
• Trough total testosterone exceeds 800 ng/dL
• Fasting triglycerides increase by more than 50% from baseline
• New or worsening obstructive sleep apnea symptoms
• PSA rises above 4.0 ng/mL or increases by more than 1.4 ng/mL within 12 months

These thresholds follow the Endocrine Society 2018 guideline [3] and apply to all patients, but South Asian men are more likely to hit the hematocrit and lipid thresholds early due to the pharmacogenomic and metabolic factors described above.

Cardiovascular Monitoring Specific to South Asian Patients

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease [8]. TRAVERSE found that testosterone replacement therapy was noninferior to placebo for major adverse cardiovascular events (MACE) over a median follow-up of 33 months. The hazard ratio for MACE was 0.96 (95% CI: 0.78 to 1.17).

Interpreting TRAVERSE for South Asian Patients

TRAVERSE provides reassurance that testosterone therapy does not dramatically increase short-term MACE risk in men already carrying cardiovascular risk factors. The trial population, however, was predominantly White (approximately 71%), with limited South Asian representation [8]. Extrapolating its safety findings to South Asian men requires caution. The QRISK3 algorithm, widely used in the UK, includes South Asian ethnicity as an independent cardiovascular risk multiplier [9]. A 50-year-old South Asian man with the same blood pressure, cholesterol, and smoking status as a White peer scores meaningfully higher on QRISK3.

Practical Monitoring Additions

Beyond the standard Endocrine Society monitoring schedule (hematocrit and testosterone at 3 to 6 months, then annually), South Asian patients benefit from:

• Fasting lipid panel at 3 months (not just 12 months)
• HbA1c at baseline and 6 months, given elevated diabetes risk
• Lipoprotein(a) measurement at baseline (Lp(a) is genetically elevated in approximately 25% of South Asian individuals [10])
• Blood pressure checks at each titration visit

Dr. Shalender Bhasin, who led the Testosterone Trials, has noted that "testosterone dose should be individualized based on the patient's serum testosterone, symptoms, and the risk-benefit ratio, especially in older men with comorbidities" [4]. For South Asian men, that risk-benefit calculation starts from a different baseline.

Body Composition and Absorption Considerations

Transdermal testosterone absorption depends partly on skin thickness, subcutaneous fat distribution, and application site blood flow. South Asian men tend to carry a higher proportion of visceral versus subcutaneous abdominal fat, which changes the pharmacokinetics of topically applied drugs in indirect but clinically relevant ways.

Visceral Fat and Aromatization

Higher visceral adiposity increases aromatase activity, converting a larger fraction of applied testosterone to estradiol. A study in Obesity Reviews documented that South Asian men have 30 to 40% more visceral fat than European men at the same BMI [11]. This increased estrogen conversion can blunt the clinical benefit of testosterone replacement while contributing to gynecomastia. Checking estradiol levels at the 4-week and 12-week marks helps identify men who may need dose adjustment or, in refractory cases, co-management with a low-dose aromatase inhibitor.

Application Site Selection

The FDA-approved application sites for AndroGel 1.62% are the shoulders and upper arms. For AndroGel 1%, the approved sites include the shoulders, upper arms, and abdomen [12]. In men with significant truncal adiposity, applying gel to the upper arms or shoulders (where subcutaneous fat tends to be thinner) may improve consistency of absorption. Instruct patients to apply to clean, dry skin without occlusion and to avoid showering or swimming for at least 2 hours post-application.

Drug Interactions Relevant to South Asian Populations

South Asian men with comorbid type 2 diabetes and dyslipidemia are frequently prescribed metformin, statins, and antihypertensives. Several of these interact with testosterone metabolism or monitoring parameters.

Metformin

Metformin modestly increases testosterone levels in men with type 2 diabetes, likely through reductions in insulin and SHBG [13]. A man already on 2,000 mg daily metformin who starts AndroGel may see a larger rise in free testosterone than expected from the gel alone. Factor this in during titration.

Statins

Statins, particularly rosuvastatin and atorvastatin, can lower total testosterone slightly by reducing cholesterol substrate for steroidogenesis. A study in the Journal of Sexual Medicine found that statin use was associated with a 3 to 4% decline in total testosterone [14]. This interaction is small but relevant when interpreting borderline-low testosterone results in South Asian men already on statin therapy.

Anticoagulants and Antiplatelets

Testosterone potentiates the effect of warfarin by increasing clotting factor catabolism. South Asian men on warfarin for atrial fibrillation or mechanical valve replacement need more frequent INR monitoring during the first 3 months of testosterone initiation. The Endocrine Society guideline specifically flags this interaction [3].

When Genetic Testing Is Worth Ordering

Routine pharmacogenomic testing before starting AndroGel is not standard of care. But in specific clinical scenarios, genotyping for UGT2B17 can change management.

Consider ordering UGT2B17 genotyping if a South Asian patient:

• Develops erythrocytosis (hematocrit above 52%) within 8 weeks of starting a low dose
• Shows trough testosterone above 700 ng/dL at the lowest available dose
• Has a first-degree relative who experienced polycythemia on testosterone therapy

The test is available through commercial pharmacogenomic panels (such as those offered by OneOme or Tempus) and costs $200 to $400 out of pocket when not covered by insurance. A confirmed del/del genotype supports using the lowest dose step (20.25 mg/day of 1.62% formulation) as a hard ceiling, with switches to alternative formulations (intramuscular testosterone cypionate at longer intervals, for example) if trough levels remain supratherapeutic.

Long-Term Follow-Up and Prostate Screening

South Asian men have a lower age-adjusted incidence of prostate cancer than White or Black men in most registry data [15]. This does not eliminate the need for PSA monitoring on testosterone therapy, but it contextualizes the numbers. The Endocrine Society recommends PSA screening at 3 to 6 months after initiation, then annually per age-appropriate guidelines [3].

A PSA that rises from 0.8 to 1.5 ng/mL in the first 6 months of TRT is typical and does not warrant biopsy referral in most cases. A PSA velocity exceeding 0.75 ng/mL per year or an absolute value above 4.0 ng/mL should prompt urology consultation, same as in any population.